No. Some studies have suggested a potential link between nicotine and a reduction in the body’s ability to fight cancer which can be serious. But there are no studies of which we are aware, that have shown that nicotine consumption/exposure causes cancer. CIGARETTES cause cancer because of the combustion method of delivery. Nicotine is an addictive substance that causes most people to continue smoking cigarettes. It is the tar and over 40 other chemicals produced from combustion of the cigarette, that cause cancer.
Nicotine is a powerful and addictive drug and can be harmful or even fatal at higher doses. There are few if any good reasons for young people to have any exposure to nicotine even under the strictest medical circumstances. There is no medical justification for smoking cigarettes: nicotine administration via smoking should always be avoided. Very small amounts of nicotine received in a non-combustible form are not known to cause significant negative health effects. According to Public Health England, and arm of the Government of the UK about the use of nicotine found in nicotine replacement therapies or “NRTs”, “The risks of nicotine use are likely to be very low or negligible. NRT is safe and licenced for use in pregnancy and for people with cardiovascular disease”.
There is emerging evidence that nicotine – administered other than via smoking – also has positive health outcomes previously not known.
Levels of dopamine, serotonin and norepinephrine are all elevated with nicotine use.
Lexaria Nicotine LLC does not manufacture or sell any nicotine products. What we do is license our patented technology to other companies that want to deliver nicotine in disruptive new product classes that offer reduced harm compared to traditional cigarettes. Several terms are being used today to describe the possibility of moving society away from combustible cigarettes: Reduced Risk; Reduced Harm; Risk Reduction; Combustion-Free; Smokeless. What all these terms have in common is the desire to recognize the need of supplying nicotine to those who wish to use it, in a manner that is less harmful than combustible cigarettes. Lexaria Nicotine LLC wants to help save lives by offering our technology to reduced-risk nicotine manufacturers and helping current or prospective smokers to choose a reduced harm alternative.
Lexaria Nicotine LLC was created in the summer of 2018 as a wholly-owned subsidiary to its parent company Lexaria Biosciences Corp, which is a publicly traded company in both the USA and Canada. Lexaria Nicotine LLC. is focused on only the global nicotine industry and has no other business interests.
The global tobacco market is US$760 billion, excluding China. If all forms of nicotine are included, and if the Chinese market is included, then the global nicotine market is estimated at roughly US$1,000 billion per year, making it one of the largest industries on earth. There are over one billion customers for nicotine products around the world.
Lexaria’s DehydraTECH technology is patent-granted in the USA and Australia for the delivery of nicotine. It is patent-pending in over 40 other countries around the word. Lexaria Nicotine LLC holds the exclusive global license from its parent company Lexaria Bioscience Corp, for commercial opportunities related to nicotine delivery that utilizes DehydraTECH. Lexaria’s intellectual property is quite strong and includes composition of matter patents as well as process patents.